Lexeo Therapeutics LXEO
NASDAQ LXEO
$4.89 +0.05 (+1.03%)
As of: Sep 4, 2026 · 3:59 PM EDT

Lexeo Therapeutics (LXEO) Net Equity Issued and Repurchased (2025 - 2026)

Lexeo Therapeutics (LXEO) posted Net Equity Issued and Repurchased of $143000.0 for Q1 2026, up 14400.0% sequentially from -$1000.0 in Q4 2025, and down 15.88% YoY from $170000.0 in Q1 2025.

Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo
Analysis

Lexeo Therapeutics (LXEO) Net Equity Issued and Repurchased (2025 - 2026) Analysis & Trends

Lexeo Therapeutics has reported Net Equity Issued and Repurchased for 2 years, with the latest figure at $143000.0 in Q1 2026.

  • Quarterly Net Equity Issued and Repurchased fell 15.88% year-over-year to $143000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $243000.0 (changed N/A YoY) and the FY2025 annual result came in at $270000.0, changed N/A from the prior year.
  • Net Equity Issued and Repurchased rose to $143000.0 in Q1 2026 per LXEO's latest filing, from -$1000.0 in the prior quarter.
  • Over five years, Net Equity Issued and Repurchased peaked at $170000.0 in Q1 2025 and troughed at -$1000.0 in Q4 2025.
Peer Set

Peer Comparison

All peers
# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Equity Issued and Repurchased (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 49.20 Mn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn -
5 Revolution Medicines 44.33 Bn 44.33 Bn - 141.90 Mn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn -
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn -
8 Royalty Pharma 28.45 Bn 27.61 Bn - -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn -
10 Lexeo Therapeutics 419.14 Mn 419.14 Mn - 25.00 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 25.00 Mn
Mar 31, 2026 143,000.00
Dec 31, 2025 -1,000.00
Sep 30, 2025 271,000.00
Jun 30, 2025 -170,000.00
Mar 31, 2025 170,000.00